查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611892

口乾症治療藥物市場：按產品、藥物類型、分銷管道 - 全球預測 2025-2030

Xerostomia Therapeutics Market by Offering (OTC, Prescription), Drug Type (Dentifrices, Salivary Stimulants, Salivary Substitutes), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年口乾症治療藥物市值為22.4億美元，預計2024年將達23.5億美元，複合年成長率為4.60%，到2030年將達到30.7億美元。

口乾症治療藥物市場的重點是解決因藥物副作用、修格蘭氏症候群自體免疫疾病以及化療和放射線治療。由於口乾症藥物對患者生活品質的影響，包括咀嚼、吞嚥和說話困難以及增加的牙齒健康問題，因此需要強調口乾症藥物的需求。最終用途包括止涎劑、唾液替代和全身止涎劑等藥物，並包括醫院、牙科診所、居家照護等。市場成長受到修格蘭氏症候群盛行率上升和人口老化導致口乾疾病盛行率增加等因素的影響。有可能開發出副作用較少、療效較好的新型治療劑，特別是對於接受放射治療或患有自體免疫疾病的患者。

主要市場統計
基準年[2023] 22.4億美元
預計年份 [2024] 23.5億美元
預測年份 [2030] 30.7億美元
複合年成長率（%） 4.60%

然而，現有的治療方法通常只能提供暫時的緩解，創新治療方法的成本很高，而且大眾對口乾症影響的認知有限，因此市場面臨著限制。另一個問題是新藥認證規定嚴格，需要大規模臨床試驗。對於創新，研究可以集中於配製長效生技藥品、探索基因治療方案以及增強現有解決方案的輸送系統。此外，利用數位健康技術開發更好的病患教育和監測工具有可能顯著改善病患的治療結果和對治療計畫的依從性。市場競爭程度為中等到高度，多家老牌和新興企業公司推動研發。優先考慮藥物開發策略聯盟、投資個人化醫療並專注於新興市場地理擴張的公司有潛力佔領重要的市場佔有率並實現持續成長。

市場動態：揭示快速發展的口乾症藥物市場的關鍵市場洞察

口乾症藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老化社會口乾症增加
    • 提高對口乾症相關產品的認知
    • 持續研究和開發，以有效開發口乾症產品
  • 市場限制因素
    • 與口乾症治療相關的藥物和治療成本上升
  • 市場機會
    • 改善口乾症的藥物和治療方法
    • 研究口乾症治療藥物有效性的臨床試驗
  • 市場挑戰
    • 關於口乾症產品行銷和銷售的嚴格規定

波特的五力：駕馭口乾症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解口乾症治療市場的外在影響

外部宏觀環境因素在塑造口乾症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解口乾症治療藥物市場的競爭狀況

對口乾症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣口乾症治療市場供應商的績效評估

FPNV定位矩陣是評估口乾症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪口乾症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，口乾症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老化社會口乾症發生率增加
      • 提高對口乾症相關產品的認知
      • 持續研發，開發針對口乾症的有效產品
    • 抑制因素
      • 與口乾症治療相關的藥物和治療費用高昂
    • 機會
      • 口乾症藥物和治療方法的進展
      • 研究口乾症治療藥物有效性的臨床試驗
    • 任務
      • 關於口乾症產品行銷和銷售的嚴格規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章口乾症治療藥物市場：透過提供

  • 在商店
  • 處方箋

第 7 章：按藥物類型分類的口乾症治療市場

  • 牙膏
  • 唾液分泌興奮劑
  • 唾液替代品

第8章口乾症治療藥物市場：按分銷管道

  • 醫院
  • 藥局
    • 離線
    • 線上

第9章 北美和南美口乾症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區口乾症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲口乾症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 3M Company
  • Advanz Pharma Corp.
  • Bausch Health Companies Inc.
  • Bio Cosmetics Laboratories, SL
  • Biodexa Pharmaceuticals PLC
  • CCMed Ltd.
  • Chattem, Inc. by Sanofi SA
  • Cipla Ltd.
  • Colgate-Palmolive Company
  • Cyclacel Pharmaceuticals, Inc.
  • Forward Science
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • ICPA Health Products Ltd
  • Lupin Limited
  • Mission Pharmacal Company
  • Parnell Pharmaceuticals Inc.
  • Perrigo Company plc
  • Pharmascience Inc.
  • Quest Products Inc.
  • Saliwell Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Synedgen Inc.
Product Code: MRR-8E22B61932BB

The Xerostomia Therapeutics Market was valued at USD 2.24 billion in 2023, expected to reach USD 2.35 billion in 2024, and is projected to grow at a CAGR of 4.60%, to USD 3.07 billion by 2030.

The xerostomia therapeutics market focuses on addressing dry mouth conditions resulting from reduced or absent saliva production, often due to medication side effects, autoimmune diseases like Sjogren's syndrome, or treatments like chemotherapy and radiation. The necessity of xerostomia therapeutics is underscored by its impact on patients' quality of life, leading to difficulties in chewing, swallowing, speaking, and increased dental health issues. Key applications include pharmaceutical agents such as saliva stimulants, saliva substitutes, and systemic sialogogues, with end-use contexts covering hospitals, dental clinics, and homecare settings. Market growth is influenced by factors like rising incidences of Sjogren's syndrome and the aging population, which increases the prevalence of conditions contributing to xerostomia. There is a potential opportunity in the development of novel therapeutics with fewer side effects and improved efficacy, particularly for patients undergoing radiotherapy or those suffering from autoimmune disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 2.24 billion
Estimated Year [2024] USD 2.35 billion
Forecast Year [2030] USD 3.07 billion
CAGR (%) 4.60%

However, the market faces limitations due to the often temporary relief offered by existing treatments, high costs associated with innovative therapies, and limited awareness of xerostomia's impact among the general population. Challenges also include stringent regulatory pathways for new drug approvals and the need for extensive clinical trials. For innovation, research could focus on formulating long-acting biologics, exploring gene therapy options, and enhancing delivery systems for existing solutions. Additionally, leveraging digital health technologies to create better patient education and monitoring tools could substantially improve patient outcomes and adherence to treatment plans. The market is characterized by a moderate to high level of competition, with several established players and emerging startups driving research and development. Companies that prioritize strategic collaborations for drug development, invest in personalized medicine, and focus on expanding geographical reach into emerging markets may capture significant market shares and achieve sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Xerostomia Therapeutics Market

The Xerostomia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of xerostomia in the aging population
    • Growing awareness about xerostomia-related products
    • Ongoing research and development for the development of efficient products for xerostomia
  • Market Restraints
    • High cost of medications and medical treatments associated with xerostomia therapies
  • Market Opportunities
    • Improvements in xerostomia drugs and treatments
    • Clinical trials to study the efficacy of xerostomia drugs
  • Market Challenges
    • Strict regulations pertaining to marketing and selling xerostomia-related products

Porter's Five Forces: A Strategic Tool for Navigating the Xerostomia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Xerostomia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Xerostomia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Xerostomia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Xerostomia Therapeutics Market

A detailed market share analysis in the Xerostomia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Xerostomia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Xerostomia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Xerostomia Therapeutics Market

A strategic analysis of the Xerostomia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Xerostomia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Advanz Pharma Corp., Bausch Health Companies Inc., Bio Cosmetics Laboratories, S.L., Biodexa Pharmaceuticals PLC, CCMed Ltd., Chattem, Inc. by Sanofi S.A., Cipla Ltd., Colgate-Palmolive Company, Cyclacel Pharmaceuticals, Inc., Forward Science, Fresenius Kabi AG, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, ICPA Health Products Ltd, Lupin Limited, Mission Pharmacal Company, Parnell Pharmaceuticals Inc., Perrigo Company plc, Pharmascience Inc., Quest Products Inc., Saliwell Ltd, Sun Pharmaceutical Industries Ltd., and Synedgen Inc..

Market Segmentation & Coverage

This research report categorizes the Xerostomia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across OTC and Prescription.
  • Based on Drug Type, market is studied across Dentifrices, Salivary Stimulants, and Salivary Substitutes.
  • Based on Distribution Channel, market is studied across Hospital and Pharmacies. The Pharmacies is further studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of xerostomia in the aging population
      • 5.1.1.2. Growing awareness about xerostomia-related products
      • 5.1.1.3. Ongoing research and development for the development of efficient products for xerostomia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of medications and medical treatments associated with xerostomia therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in xerostomia drugs and treatments
      • 5.1.3.2. Clinical trials to study the efficacy of xerostomia drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulations pertaining to marketing and selling xerostomia-related products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Xerostomia Therapeutics Market, by Offering

  • 6.1. Introduction
  • 6.2. OTC
  • 6.3. Prescription

7. Xerostomia Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Dentifrices
  • 7.3. Salivary Stimulants
  • 7.4. Salivary Substitutes

8. Xerostomia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Pharmacies
    • 8.3.1. Offline
    • 8.3.2. Online

9. Americas Xerostomia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Xerostomia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Xerostomia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Advanz Pharma Corp.
  • 3. Bausch Health Companies Inc.
  • 4. Bio Cosmetics Laboratories, S.L.
  • 5. Biodexa Pharmaceuticals PLC
  • 6. CCMed Ltd.
  • 7. Chattem, Inc. by Sanofi S.A.
  • 8. Cipla Ltd.
  • 9. Colgate-Palmolive Company
  • 10. Cyclacel Pharmaceuticals, Inc.
  • 11. Forward Science
  • 12. Fresenius Kabi AG
  • 13. Fresenius SE & Co. KGaA
  • 14. GlaxoSmithKline PLC
  • 15. Hikma Pharmaceuticals PLC
  • 16. ICPA Health Products Ltd
  • 17. Lupin Limited
  • 18. Mission Pharmacal Company
  • 19. Parnell Pharmaceuticals Inc.
  • 20. Perrigo Company plc
  • 21. Pharmascience Inc.
  • 22. Quest Products Inc.
  • 23. Saliwell Ltd
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Synedgen Inc.

LIST OF FIGURES

  • FIGURE 1. XEROSTOMIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. XEROSTOMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. XEROSTOMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. XEROSTOMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. XEROSTOMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. XEROSTOMIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OTC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DENTIFRICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY SALIVARY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY SALIVARY SUBSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM XEROSTOMIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 188. XEROSTOMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. XEROSTOMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023